{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:31:14Z","timestamp":1791959474875,"version":"4.3.4"},"reference-count":112,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Biotest AG, Dreieich, Germany"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.trre.2017.01.001","type":"journal-article","created":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T05:46:17Z","timestamp":1484804777000},"page":"78-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immunomodulation by hyperimmunoglobulins after solid organ transplantation: Beyond prevention of viral infection"],"prefix":"10.1016","volume":"31","author":[{"given":"Rogier","family":"van Gent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herold J.","family":"Metselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Kwekkeboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2017.01.001_bb0005","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2017.01.001_bb0010","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.it.2008.08.004","article-title":"Modulation of the cellular immune system by intravenous immunoglobulin","volume":"29","author":"Tha-In","year":"2008","journal-title":"Trends Immunol"},{"key":"10.1016\/j.trre.2017.01.001_bb0015","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaci.2010.10.030","article-title":"The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders","volume":"127","author":"Ballow","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.trre.2017.01.001_bb0020","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.trre.2017.01.001_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2014.05.002","article-title":"Fragments of truth: T-cell targets of polyclonal immunoglobulins in autoimmune diseases","volume":"17","author":"Petta","year":"2014","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.trre.2017.01.001_bb0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3389\/fimmu.2015.00197","article-title":"Differences in anti-inflammatory actions of intravenous immunoglobulin between mice and men: more than meets the eye","volume":"6","author":"Tjon","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.trre.2017.01.001_bb0035","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.4049\/jimmunol.1301260","article-title":"Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production","volume":"192","author":"Tjon","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.trre.2017.01.001_bb0040","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature10134","article-title":"Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway","volume":"475","author":"Anthony","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.trre.2017.01.001_bb0045","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/cei.12102","article-title":"Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells","volume":"173","author":"Tjon","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.trre.2017.01.001_bb0050","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jpeds.2004.05.048","article-title":"CD25+CD4+ regulatory T cells in patients with Kawasaki disease","volume":"145","author":"Furuno","year":"2004","journal-title":"J Pediatr"},{"key":"10.1016\/j.trre.2017.01.001_bb0055","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3899\/jrheum.111123","article-title":"Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease","volume":"39","author":"Bayry","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.trre.2017.01.001_bb0060","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1154315","article-title":"Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG fc","volume":"320","author":"Anthony","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.trre.2017.01.001_bb0065","doi-asserted-by":"crossref","first-page":"19571","DOI":"10.1073\/pnas.0810163105","article-title":"Identification of a receptor required for the anti-inflammatory activity of IVIG","volume":"105","author":"Anthony","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trre.2017.01.001_bb0070","doi-asserted-by":"crossref","first-page":"E1297","DOI":"10.1073\/pnas.1422481112","article-title":"Controlled tetra-fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity","volume":"112","author":"Washburn","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trre.2017.01.001_bb0075","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jaci.2013.09.029","article-title":"Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells","volume":"133","author":"Massoud","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.trre.2017.01.001_bb0080","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1182\/blood-2009-12-261461","article-title":"IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes","volume":"116","author":"Seite","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.trre.2017.01.001_bb0085","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/j.1600-6143.2005.01029.x","article-title":"Hepatitis B immunoglobulins inhibit dendritic cells and T cells and protect against acute rejection after liver transplantation","volume":"5","author":"Kwekkeboom","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.01.001_bb0090","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.intimp.2014.01.007","article-title":"T-cell inhibitory capacity of hyperimmunoglobulins is influenced by the production process","volume":"19","author":"van Gent","year":"2014","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.trre.2017.01.001_bb0095","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1097\/01.tp.0000226073.20185.b1","article-title":"Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: comparison to calcineurin inhibitors","volume":"81","author":"Tha-In","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.01.001_bb0100","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1365-2362.2007.01881.x","article-title":"Cytomegalovirus hyperimmunoglobulin: mechanisms in allo-immune response in vitro","volume":"37","author":"Hoetzenecker","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.trre.2017.01.001_bb0105","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJM199806113382407","article-title":"Infection in organ-transplant recipients","volume":"338","author":"Fishman","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2017.01.001_bb0110","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/10898540-000000000-00000","article-title":"New developments in the management of cytomegalovirus infection after solid organ transplantation","volume":"70","author":"Eid","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.trre.2017.01.001_bb0115","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4254\/wjh.v2.i9.325","article-title":"Current concepts on cytomegalovirus infection after liver transplantation","volume":"2","author":"Lee","year":"2010","journal-title":"World J Hepatol"},{"key":"10.1016\/j.trre.2017.01.001_bb0120","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s12026-012-8304-8","article-title":"Diverse immune evasion strategies by human cytomegalovirus","volume":"54","author":"Noriega","year":"2012","journal-title":"Immunol Res"},{"key":"10.1016\/j.trre.2017.01.001_bb0125","doi-asserted-by":"crossref","first-page":"13947","DOI":"10.1128\/JVI.02424-14","article-title":"Latency-associated viral interleukin-10 (IL-10) encoded by human cytomegalovirus modulates cellular IL-10 and CCL8 secretion during latent infection through changes in the cellular microRNA hsa-miR-92a","volume":"88","author":"Poole","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.trre.2017.01.001_bb0130","doi-asserted-by":"crossref","first-page":"9618","DOI":"10.1128\/JVI.01098-09","article-title":"Virus-encoded homologs of cellular interleukin-10 and their control of host immune function","volume":"83","author":"Slobedman","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.trre.2017.01.001_bb0135","doi-asserted-by":"crossref","first-page":"e1002850","DOI":"10.1371\/journal.ppat.1002850","article-title":"Immune senescence: relative contributions of age and cytomegalovirus infection","volume":"8","author":"Mekker","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.trre.2017.01.001_bb0140","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.4049\/jimmunol.1201867","article-title":"Lifelong persistent viral infection alters the naive T cell pool, impairing CD8 T cell immunity in late life","volume":"189","author":"Smithey","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.trre.2017.01.001_bb0145","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/infdis\/jit064","article-title":"Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients","volume":"207","author":"Courivaud","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2017.01.001_bb0150","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1164\/rccm.200911-1786OC","article-title":"Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation","volume":"181","author":"Snyder","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.trre.2017.01.001_bb0155","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1111\/j.1600-6143.2011.03663.x","article-title":"Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome","volume":"11","author":"Paraskeva","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.01.001_bb0160","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/TP.0000000000000160","article-title":"Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment","volume":"98","author":"Stern","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.01.001_bb0165","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1681\/ASN.2009111188","article-title":"Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation","volume":"21","author":"Smith","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2017.01.001_bb0170","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1473-3099(02)00370-5","article-title":"Infections and solid organ transplant rejection: a cause-and-effect relationship?","volume":"2","author":"Cainelli","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trre.2017.01.001_bb0175","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/cid\/cir619","article-title":"Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival","volume":"53","author":"Dzabic","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2017.01.001_bb0180","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1182\/blood-2009-07-234906","article-title":"Allo-HLA reactivity of virus-specific memory T cells is common","volume":"115","author":"Amir","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.trre.2017.01.001_bb0185","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1681\/ASN.2013101052","article-title":"Cytomegalovirus-responsive gammadelta T cells: novel effector cells in antibody-mediated kidney allograft microcirculation lesions","volume":"25","author":"Bachelet","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2017.01.001_bb0190","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1600-6143.2004.00505.x","article-title":"Cytomegalovirus and lung transplantation","volume":"4","author":"Zamora","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.01.001_bb0195","first-page":"669","article-title":"Post-transplant lymphoproliferative disorders in renal transplantation: two decades of experience","volume":"30","author":"Franco","year":"2010","journal-title":"Nefrologia"},{"key":"10.1016\/j.trre.2017.01.001_bb0200","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.transproceed.2010.02.042","article-title":"Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia","volume":"42","author":"Kim","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2017.01.001_bb0205","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.tp.0000179639.98338.39","article-title":"Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression","volume":"80","author":"Caillard","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.01.001_bb0210","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1399-3046.2008.00969.x","article-title":"Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients","volume":"13","author":"Schubert","year":"2009","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2017.01.001_bb0215","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00007890-197901000-00017","article-title":"Cytomegalovirus immune globulin: production from selected normal donor blood","volume":"27","author":"Zaia","year":"1979","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.01.001_bb0220","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1056\/NEJM198710223171703","article-title":"Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients","volume":"317","author":"Snydman","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2017.01.001_bb0225","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/00007890-198908000-00016","article-title":"Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated for rejection","volume":"48","author":"Metselaar","year":"1989","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.01.001_bb0230","doi-asserted-by":"crossref","first-page":"984","DOI":"10.7326\/0003-4819-119-10-199311150-00004","article-title":"Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial","volume":"119","author":"Snydman","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trre.2017.01.001_bb0235","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1399-0012.2007.00750.x","article-title":"CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis","volume":"22","author":"Bonaros","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2017.01.001_bb0240","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/01.TP.0000119722.37337.DC","article-title":"Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients","volume":"77","author":"Bonaros","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.01.001_bb0245","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(05)66553-1","article-title":"Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials","volume":"365","author":"Hodson","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2017.01.001_bb0250","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1111\/j.1600-6143.2009.02897.x","article-title":"Cytomegalovirus in solid organ transplant recipients","volume":"9","author":"Humar","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.01.001_bb0255","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.01.001_bb0260","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-152-12-201006150-00003","article-title":"Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial","volume":"152","author":"Palmer","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trre.2017.01.001_bb0265","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1600-6143.2012.04339.x","article-title":"Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis?","volume":"13","author":"Schoeppler","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.01.001_bb0270","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.transproceed.2011.02.069","article-title":"Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation","volume":"43","author":"Snydman","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2017.01.001_bb0275","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S1053-2498(02)00648-4","article-title":"Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients","volume":"22","author":"Kruger","year":"2003","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2017.01.001_bb0280","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1097\/00007890-200111270-00012","article-title":"Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone","volume":"72","author":"Valantine","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.01.001_bb0285","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/01.tp.0000209439.27719.ed","article-title":"Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation","volume":"81","author":"Ruttmann","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.01.001_bb0290","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1053-2498(00)00426-5","article-title":"Monthly infusion of cytomegalovirus immune globulin (CMVIG) decreases the incidence of bacterial and fungal infections in the first year following lung transplantation","volume":"20","author":"Zamora","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2017.01.001_bb0295","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.healun.2009.04.032","article-title":"Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation","volume":"28","author":"Ranganathan","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2017.01.001_bb0300","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/TP.0b013e31827df7a7","article-title":"Effect of cytomegalovirus immunoglobulin on the incidence of lymphoproliferative disease after lung transplantation: single-center experience with 1157 patients","volume":"95","author":"Jaksch","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.01.001_bb0305","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(07)70040-2","article-title":"Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis","volume":"8","author":"Opelz","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.trre.2017.01.001_bb0310","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1034\/j.1399-3062.2001.00008.x","article-title":"Hypogammaglobulinemia after heart transplantation: impact of pre-emptive use of immunoglobulin replacement (CytoGam) on infection and rejection outcomes","volume":"3","author":"Yamani","year":"2001","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2017.01.001_bb0315","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/01.tp.0000229039.87735.76","article-title":"Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection","volume":"82","author":"Potena","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.01.001_bb0320","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1097\/TP.0b013e3181ffba7e","article-title":"Cytomegalovirus prevention and long-term recipient and graft survival in pediatric heart transplant recipients","volume":"90","author":"Snydman","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.01.001_bb0325","doi-asserted-by":"crossref","first-page":"E455","DOI":"10.1111\/j.1399-0012.2011.01459.x","article-title":"The impact of CMV prevention on long-term recipient and graft survival in heart transplant recipients: analysis of the scientific registry of transplant recipients (SRTR) database","volume":"25","author":"Snydman","year":"2011","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2017.01.001_bb0330","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/hep.510230207","article-title":"Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins","volume":"23","author":"Farges","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.trre.2017.01.001_bb0335","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1399-0012.1997.tb00847.x","article-title":"Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG study group","volume":"11","author":"Falagas","year":"1997","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2017.01.001_bb0340","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/lt.21843","article-title":"Treatment with immunoglobulin improves outcome for pediatric liver transplant recipients","volume":"15","author":"Bucuvalas","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2017.01.001_bb0345","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/lt.20523","article-title":"Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation","volume":"11","author":"Slifkin","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2017.01.001_bb0350","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1399-3062.2011.00664.x","article-title":"The association between cytomegalovirus immune globulin and long-term recipient and graft survival following liver transplantation","volume":"14","author":"Fisher","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2017.01.001_bb0355","first-page":"1357","article-title":"Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials","volume":"23","author":"Snydman","year":"1991","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2017.01.001_bb0360","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/hep.1840130402","article-title":"Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease","volume":"13","author":"Todo","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.trre.2017.01.001_bb0365","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0168-8278(92)90138-F","article-title":"Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications","volume":"14","author":"O'Grady","year":"1992","journal-title":"J Hepatol"},{"key":"10.1016\/j.trre.2017.01.001_bb0370","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0140-6736(91)92515-4","article-title":"Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients","volume":"337","author":"Samuel","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2017.01.001_bb0375","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJM199312163292503","article-title":"Liver transplantation in European patients with the hepatitis B surface antigen","volume":"329","author":"Samuel","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2017.01.001_bb0380","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/00000658-199806000-00007","article-title":"Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization","volume":"227","author":"Sawyer","year":"1998","journal-title":"Ann Surg"},{"key":"10.1016\/j.trre.2017.01.001_bb0385","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0168-8278(05)80396-4","article-title":"Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients","volume":"21","author":"Devlin","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.trre.2017.01.001_bb0390","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/lt.22354","article-title":"Hepatitis B immunoglobulin and\/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review","volume":"17","author":"Cholongitas","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2017.01.001_bb0395","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/lt.23690","article-title":"Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B","volume":"19","author":"Perrillo","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2017.01.001_bb0400","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-6143.2012.04315.x","article-title":"High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review","volume":"13","author":"Cholongitas","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.01.001_bb0405","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/lt.23408","article-title":"Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation","volume":"18","author":"Laryea","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2017.01.001_bb0410","first-page":"312","article-title":"HBIG remains significant in the era of new potent nucleoside analogues for prophylaxis against hepatitis B recurrence after liver transplantation","volume":"35","author":"Kasraianfard","year":"2014","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.trre.2017.01.001_bb0415","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/lt.23628","article-title":"Randomized trial of emtricitabine\/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation","volume":"19","author":"Teperman","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2017.01.001_bb0420","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/jhep.2001.21554","article-title":"A multicenter United States\u2013Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B","volume":"33","author":"Perrillo","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.trre.2017.01.001_bb0425","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/lt.20981","article-title":"Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results","volume":"13","author":"Schiff","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2017.01.001_bb0430","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1053\/j.gastro.2011.06.083","article-title":"Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation","volume":"141","author":"Fung","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.trre.2017.01.001_bb0435","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ajg.2013.111","article-title":"Oral nucleoside\/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B","volume":"108","author":"Fung","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.trre.2017.01.001_bb0440","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000360944","article-title":"Prevention of hepatitis B virus reinfection in liver transplant recipients","volume":"57","author":"Roche","year":"2014","journal-title":"Intervirology"},{"key":"10.1016\/j.trre.2017.01.001_bb0445","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1590\/S0036-46652001000600007","article-title":"Human polyclonal anti-hepatitis B surface antigen immunoglobulin reduces the frequency of acute rejection after liver transplantation for chronic hepatitis B","volume":"43","author":"Couto","year":"2001","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"10.1016\/j.trre.2017.01.001_bb0450","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1111\/j.1432-2277.2011.01334.x","article-title":"Chronic rejection related to hepatitis B immunoglobulin discontinuation in a liver transplant recipient","volume":"24","author":"Wong","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2017.01.001_bb0455","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/hep.510280306","article-title":"Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome","volume":"28","author":"Wiesner","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.trre.2017.01.001_bb0460","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1432-2277.2011.01236.x","article-title":"Prophylaxis against de novo hepatitis B for liver transplantation utilizing hep B core (+) donors: does hepatitis B immunoglobulin provide a survival advantage?","volume":"24","author":"Brock","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2017.01.001_bb0465","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/lt.23774","article-title":"Use of hepatitis B surface antigen-positive grafts in liver transplantation: a matched analysis of the US national database","volume":"20","author":"Li","year":"2014","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2017.01.001_bb0470","doi-asserted-by":"crossref","first-page":"e104480","DOI":"10.1371\/journal.pone.0104480","article-title":"Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.trre.2017.01.001_bb0475","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/ncprheum0481","article-title":"Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action","volume":"3","author":"Bayry","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.trre.2017.01.001_bb0480","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial","volume":"15","author":"Jordan","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2017.01.001_bb0485","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.tmrv.2009.09.010","article-title":"The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline","volume":"24","author":"Shehata","year":"2010","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.trre.2017.01.001_bb0490","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1600-6143.2010.03400.x","article-title":"Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients","volume":"11","author":"Jordan","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.01.001_bb0495","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/bmb\/ldv013","article-title":"Kidney transplantation in highly sensitized patients","volume":"114","author":"Jordan","year":"2015","journal-title":"Br Med Bull"},{"key":"10.1016\/j.trre.2017.01.001_bb0500","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/TP.0000000000000064","article-title":"Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients","volume":"98","author":"Vo","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.01.001_bb0505","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00007890-200108150-00010","article-title":"Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients","volume":"72","author":"Luke","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.01.001_bb0510","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00007890-200101150-00009","article-title":"A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection","volume":"71","author":"Casadei","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.01.001_bb0515","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/00007890-199809270-00017","article-title":"Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action","volume":"66","author":"Jordan","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.01.001_bb0520","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1097\/01.TP.0000090868.88895.E0","article-title":"Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients","volume":"76","author":"Zachary","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2017.01.001_bb0525","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1012376","article-title":"Desensitization in HLA-incompatible kidney recipients and survival","volume":"365","author":"Montgomery","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2017.01.001_bb0530","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/ajt.12786","article-title":"Quantifying the risk of incompatible kidney transplantation: a multicenter study","volume":"14","author":"Orandi","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.01.001_bb0535","doi-asserted-by":"crossref","first-page":"R193","DOI":"10.1186\/ar2892","article-title":"Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study","volume":"11","author":"van de Geijn","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.trre.2017.01.001_bb0540","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1021\/pr401213z","article-title":"IgG fc N-glycosylation in Guillain\u2013Barre syndrome treated with immunoglobulins","volume":"13","author":"Fokkink","year":"2014","journal-title":"J Proteome Res"},{"key":"10.1016\/j.trre.2017.01.001_bb0545","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/jnnp-2012-304670","article-title":"Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy","volume":"84","author":"Kuitwaard","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.trre.2017.01.001_bb0550","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/j.1600-6143.2011.03593.x","article-title":"High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant","volume":"11","author":"O'Leary","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.01.001_bb0555","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/ajt.12667","article-title":"The role of donor-specific HLA alloantibodies in liver transplantation","volume":"14","author":"O'Leary","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2017.01.001_bb0560","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/lt.23451","article-title":"Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation","volume":"18","author":"Kaneku","year":"2012","journal-title":"Liver Transpl"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X16300325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X16300325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T16:26:59Z","timestamp":1749918419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X16300325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":112,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0955470X16300325"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2017.01.001","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulation by hyperimmunoglobulins after solid organ transplantation: Beyond prevention of viral infection","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2017.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}